Enalapril Maleate

马来酸依那普利

Report date: 2022/08/16 20:00:19
NME

Base Information

Drug NameEnalapril Maleate
Drug Alias Name恩萘普利EnalaprilumInvoril苯丁酯脯酸恩纳普利马来酸盐 +[25] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAngiotensin-converting enzyme inhibitors
TargetsAngiotensin-converting enzyme
Therapy Area/IndicationsSolid tumoursDiabetes ComplicationsHypertension +[23] 
Global Approved IndicationsHypertensionVentricular Dysfunction, LeftMyocardial Infarction +[5] 
Approved Indications in ChinaHypertensionMyocardial InfarctionAngina Pectoris +[4] 
Original Approved Country/TerritoryUnited States
Original Approved Date1985/12/24
Country/TerritoryBelgiumCanadaUnited States +[14] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBausch Health Companies Inc
China Registration ClassN/A

Develop Information

Active CompaniesMerck Sharp & Dohme （Australia） Pty LtdEuropean Institute Of OncologyProveca Pharma Ltd +[4] 
Inactive CompaniesUtah State UniversityWake Forest UniversityUniversity Of Minnesota +[10] 
Active IndicationsHypertensionVentricular Dysfunction, LeftMyocardial Infarction +[6] 
Inactive IndicationsSolid tumoursDiabetes ComplicationsVascular Diseases +[17] 

Other Information

ATC CodeC09AA02
Related LinksWikipediaDrugBankKEGG